OBR Daily Commentary

forumImage

Take the Generic, Patients Are Told. Until They Are Not.

(New York Times/ProPublica) Aug 6, 2017 - Consumers have grown used to being told to give up their brand-name drugs in favor of cheaper generics. Now some are finding the opposite is true.

Read Article arrow

Winston Wong, PharmD (Posted: August 14, 2017)

quotesThe rationale is pretty simple. The branded drugs are now presenting deep rebate discounts, and bring the net cost to somewhere comparable to the generic/biosimilar. If the cheaper drug was dispensed outright, the only win is the patient paying the lower copay and payer experiences an immediate cost savings. If the more expensive brand is dispensed, the PBM/Payer get the rebate, of which the PBM receives a portion of, and hopefully the piece of the rebate that is passed through to the payer will bring the cost down, if they can even track it. So in essence, that final statement is very true. Someone has to be making money from the deal to make it fly.quotes

Add Comment 1 Comment
forumImage

Opinion: Who Is To Blame For Skyrocketing Drug Prices?

(The Hill) July 27, 2017 - Across the board, drug prices are soaring. Even the cost of cancer medications are so high that some patients are delaying cancer treatments or skipping them altogether.

Read Article arrow

Winston Wong, PharmD (Posted: August 04, 2017)

quotesThe finger pointing between Pharma and the PBM's is looking much like the political arena with regards to ACA. In all reality, both are stockholders and both contribute to the high cost of drugs. The last factor that no one is considering is that whatever, and wherever the price is set at, we will reimburse. That is not the case in Europe, especially in the countries mentioned. In those countries, if the price is too high, the drug is not reimbursed. quotes

Add Comment 1 Comment
forumImage

Merck, Samsung Accelerate a Biosimilar Price War

(Bloomberg) July 24, 2017 - Back in November, Pfizer Inc. launched its biosimilar of Johnson & Johnson's Remicade at just a 15 percent discount to the original's list price. That disappointed anyone hoping biosimilars would bring a golden age of cheaper drugs. But then Merck & Co. and Samsung Bioepis had to ruin the party on Monday, by launching a competing biosimilar at a 35 percent discount to Remicade's list price.

Read Article arrow

Winston Wong, PharmD (Posted: August 04, 2017)

quotesThe initial release discount of 15% by Pfizer did not spark much uptake, mainly because, in my opinion, a 15% by J&J was well within striking range. Now with a 35% discount on the table, the sandbox should become more stirred up. Not that 35% is not within J&J's range as well, but the payers need to step up to the plate and drive utilization.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...